European Organisation for Research and Treatment of Cancer

Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial

Background In classic Hodgkin lymphoma (cHL), identifying high-risk patients is crucial for tailored treatment. Clinical risk factors are useful, but there is room for improvement. Although many diagnostic tissue-based biomarkers have been described to correlate with prognosis, n...

Digital solutions for tackling mental health in cancer patients and their families: The ALTHEA project

Despite advances in cancer treatment, the growing global cancer burden underscores the need for comprehensive and supportive care to address the needs of patients and their families. However, access to psycho-oncological support remains often limited across healthcare systems. Th...

Neuralgic Amyotrophy Following Rotator Cuff Repair

Neuralgic amyotrophy (NA) is an uncommon but potentially debilitating cause of pain and weakness that is felt to be inflammatory in nature. This patient-focused case report describes the experience of a 64-year-old active male who developed severe periscapular pain eight days aft...